Impact Biomedical (IBO) Liabilities and Shareholders Equity (2022 - 2026)

Impact Biomedical (IBO) has reported Liabilities and Shareholders Equity for 5 consecutive years, with $16.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 12.15% year-over-year to $16.7 million; the trailing twelve-month figure through Jun 2026 stood at $69.4 million (down 34.55% YoY), and the FY2025 full-year result was $17.4 million, down 14.22% from the prior year.
• Liabilities and Shareholders Equity fell to $16.7 million in Q2 2026 per IBO's latest filing, from $17.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $46.7 million in Q3 2024 and bottomed at $16.7 million in Q2 2026.
• Historically, Liabilities and Shareholders Equity has averaged $31.9 million across 5 years, with a median of $32.2 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity grew 3.58% in 2024, then tumbled 61.01% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $46.5 million in 2022, then retreated by 4.01% to $44.6 million in 2023, then slumped by 54.54% to $20.3 million in 2024, then fell by 14.22% to $17.4 million in 2025, then retreated by 3.79% to $16.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $16.7 million, $17.1 million, and $17.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.